RxDoctor Payments Data

Ilan Cohen, MD

Ophthalmology · Ridgewood, NYNPI 1649374802

Payments from drug & device makers

$5,445in general payments, 2019–2025

Across 84 payments — averaging $64.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$3K
  • Alcon$1K
  • Johnson & Johnson Surgical Vision, Inc.$343
  • NEW World Medical,inc.$256
  • Amgen$137
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$86
  • plus $349 from 9 others

What the payments were for

  • Speaking & faculty fees$3,00055%
  • Food & beverage$2,44545%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,445 in reported general payments places this provider in the 75th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$403,100
Medicare patients
620
Services billed
2,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine219$247,964
ProlensaBromfenac Sodium440$151,246
BesivanceBesifloxacin Hcl220$48,190
XiidraLifitegrast34$45,329
Prednisolone Acetate931$42,541
MieboPerfluorohexyloctane/Pf50$38,085
Bromfenac Sodium186$36,212
Cyclosporine57$31,071
LumiganBimatoprost54$29,075
CombiganBrimonidine Tartrate/Timolol40$18,197
Ofloxacin668$11,155
RhopressaNetarsudil Mesylate32$9,779
Brimonidine Tartrate68$8,630
RocklatanNetarsudil Mesylat/Latanoprost27$8,628
Ketorolac Tromethamine387$6,440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$45$298,527326 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate$86$203,672681 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$78$83,41484 claims
AlconSimbrinza$1,155$3,35816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Ridgewood

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →